nach oben

Erschienen in:

01.04.2014 | Urology - Original Paper

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men

verfasst von: Luca Cindolo, Luisella Pirozzi, Caterina Fanizza, Marilena Romero, Petros Sountoulides, Claus G. Roehrborn, Vincenzo Mirone, Luigi Schips

Erschienen in: International Urology and Nephrology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system.

Methods

Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period.

Results

The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively).

Conclusions

The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’dow J, Nordling J, de la Rosette JJ (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140PubMedCrossRef

Anderson JB, Roehrborn CG, Schalken JA et al (2001) The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 39(4):390–399PubMedCrossRef

Oelke M, Gravas S (2010) Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World J Urol 28(1):1–2PubMedCentralPubMedCrossRef

Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649PubMedCrossRef

Verhamme KM, Dieleman JP, Bleumink GS et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328PubMedCrossRef

Sarma AV, Wei JT (2012) Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367(3):248–257PubMedCrossRef

Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173:1256–1261PubMedCrossRef

McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338(9):557–563PubMedCrossRef

Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R (2008) Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 62(7):1076–1086PubMedCentralPubMedCrossRef

10.

Oelke M, Bachmann A, Descazeaud A, et al. (2013) Guidelines on management of male lower urinary tract symptoms (LUTS), incl. Benign prostatic obstruction (BPO) Uroweb 2013. Last accessed 1 Aug 2013

11.

McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803PubMedCrossRef

12.

McConnell JD, Roehrborn CG, Bautista OM et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398PubMedCrossRef

13.

Füllhase C, Chapple C, Cornu JN et al (2013) Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 64(2):228–243PubMedCrossRef

14.

Cornu JN, Cussenot O, Haab F, Lukacs B (2010) A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 58(3):450–456PubMedCrossRef

15.

Nichol MB, Knight TK, Wu J et al (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181(5):2214–2221PubMedCrossRef

16.

Souverein PC, van Riemsdijk MM, de la Rosette JJ et al (2005) Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Eur Urol 47(4):505–510PubMedCrossRef

17.

Logie J, Clifford GM, Farmer RD (2005) Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU Int 95(4):557–562PubMedCrossRef

18.

Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337PubMedCrossRef

19.

WHO Collaborating Centre for Drug Statistics Methodology (2003) ATC index with DDDs. WHO, Oslo

20.

US Centers for Disease Control and Prevention. International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 1 Aug 2013

21.

Boyle P, Robertson C, Mazzetta C et al (2003) The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 92(4):409–414PubMedCrossRef

22.

AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations. J Urol 170(2 Pt 1):530–547

23.

Strope SA, Elliott SP, Saigal CS, Smith A, Wilt TJ, Wei JT (2011) Urologic diseases in America project. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology 78(1):3–9PubMedCentralPubMedCrossRef

24.

Watson V, Ryan M, Brown CT et al (2004) Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 172(6 Pt 1):2321–2325PubMedCrossRef

25.

Boyle P, Roehrborn C, Harkaway R et al (2004) 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45(5):620–626PubMedCrossRef

26.

Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131PubMedCrossRef

27.

Robert G, Descazeaud A, de la Taille A (2011) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: who are the high-risk patients and what are the best treatment options? Curr Opin Urol 21(1):42–48PubMedCrossRef

28.

Roehrborn C, Barkin J, Siami P et al (2011) Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin (CombAT) trial. BJU Int 107(6):946–954PubMedCrossRef

29.

Souverein PC, Erkens JA, de la Rosette JJ et al (2003) Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. Eur Urol 43(5):528–534PubMedCrossRef

30.

Sarrazin MS, Rosenthal GE (2012) Finding pure and simple truths with administrative data. JAMA 307(13):1433–1435PubMedCrossRef

Titel: Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men
verfasst von: Luca Cindolo
Luisella Pirozzi
Caterina Fanizza
Marilena Romero
Petros Sountoulides
Claus G. Roehrborn
Vincenzo Mirone
Luigi Schips
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2014
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-013-0587-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men